Please find the next edition of the Monthly Infectious Diseases Summary, our subjective look at the most important news of the month. Please let us know how you like it and if there is something interesting, we missed by contacting us at nac.contact@lgcgroup.com
WHO Study Lists Top Endemic Pathogens for which New Vaccines are Urgently Needed
A new WHO study in eBioMedicine identifies 17 pathogens as top priorities for vaccine development, chosen based on their regional disease burden, antimicrobial resistance, and socioeconomic impact. Longstanding targets like HIV, malaria, and tuberculosis remain crucial, but the study also emphasizes pathogens such as Group A streptococcus and Klebsiella pneumoniae, which are increasingly resistant to antimicrobials.
Ethiopia is facing a significant surge in malaria cases, with over 7.3 million infections and 1,157 deaths reported between January 1 and October 20, 2024, according to the World Health Organization (WHO). This marks the highest annual number of cases recorded in the past seven years. The majority of cases (95%) were laboratory-confirmed, with Plasmodium falciparum accounting for more than two-thirds.
UK to create world-first 'early warning system' for pandemics
The UK government has announced plans to create the world’s first real-time surveillance system for monitoring pandemic threats through a partnership with Genomics England, UK Biobank, NHS England, and Oxford Nanopore—a leader in life sciences technology. Oxford Nanopore’s long-read sequencing technology, which enables rapid analysis of genes and pathogens, will power this new system.
Rwanda is currently dealing with an outbreak of Marburg virus disease (MVD), reporting 66 confirmed cases and 15 deaths as of October 31, 2024, according to the World Health Organization (WHO). The outbreak was declared on September 27, and two new cases have been identified since the last update. Both new patients are known contacts of previously confirmed cases and are receiving treatment.
The Native Antigen Company Expands CMV Portfolio with Recombinant HCMV PP65 Antigen and Six New Antibodies
The Native Antigen Company is excited to announce the launch of the recombinant human cytomegalovirus (HCMV) PP65 antigen, along with six new recombinant antibodies (IgG and IgM) for HCMV MAB12537, MAB12538-MAB12539, MAB12540, MAB12541 andMAB12542, further expanding its CMV portfolio. These additions offer enhanced sensitivity, specificity, and scalability, providing more consistent and reliable diagnostic outcomes. By offering these advanced tools, The Native Antigen Company continues to support the fight against HCMV, advancing both diagnostics and vaccine development.
The Native Antigen Company Announces New Oropouche Virus Nucleoprotein for Research and Diagnostics
At The Native Antigen Company, we are committed to global pandemic preparedness by providing high-quality antigens for Oropouche virus research and diagnostics. We are pleased to announce the launch of our new Oropouche Virus Nucleoprotein, C-terminal His-tag (REC32118), now available for purchase.
The Native Antigen Company offers a comprehensive portfolio of Haemorrhageic Fever Viruses. Click below to download the Quick Guide now:
Nicole McIver | Associate Marketing Program Manager
Nicole lives in Massachusetts, US where she was born and raised. She completed a B.S. in Biology at Merrimack College and began working in the biotechnology industry in 2015 at Quest Diagnostics as a Molecular Medical Technologist. During her time in the molecular diagnostics laboratory Nicole worked with third-party quality controls including those from LGC Clinical Diagnostics' Seracare line.
In 2019, Nicole moved into a research role at a smaller biotech company MatTek Life Sciences where she worked with 3D bioactive lab-grown human tissue models studying the morphological, cytotoxic and genetic impacts of cosmetics and consumer products. There she performed various assays involving IHC, qPCR and ELISAs.
In 2021, Nicole chose to make a career change and pursue marketing as she found the impact of design and strategic data-driven insights intriguing. Nicole completed the MBA, Marketing program at Fitchburg State University in 2022. Her goal is to educate, excite, and connect people with the tools they need to make the world a better place.
Nicole has been with LGC Clinical Diagnostics one year this month! She is the creator behind The Native Antigen Company's email and social campaigns, and assists with websites, webinars, events and other content curation across the business.
In her free time, Nicole enjoys spending time with her fiancé, two cats, boxador dog and her nearby family. On the weekends, they usually find a local trail to hike, a festival with live music and food trucks, or stay in to play board games or watch a movie.
Nicole looks forward to continue to share the ongoing excitement here!
LGC Clinical Diagnostics, lgcclinicaldiagnostics.com, 37 Birch St., Milford, MA 01757, United States, 800.333.0958
